Association between erectile dysfunction and functionality of the spousal subsystem in patients with benign prostatic hyperplasia
Association between erectile dysfunction and functionality of the spousal subsystem in patients with benign prostatic hyperplasia
DOI:
https://doi.org/10.59420/remus.5.2021.21Keywords:
Prostatic hyperplasia, erectile dysfunction, conjugal subsystemAbstract
Introduction: Benign Prostatic Hyperplasia (BPH) is a common pathology in patients over 40 years of age. The use of drugs such as tamsulosin and finasteride considerably reduce obstructive and irritative symptoms, therefore only a small percentage require surgical treatment. Among the side effects of the medical treatment is erectile dysfunction, which can affect the quality of life of those who use it, as well as the functionality of the conjugal subsystem. The main objective is to determine if there is an association between erectile dysfunction and the functionality of the spousal subsystem in patients with benign prostatic hyperplasia.
Material and methods: An observational, cross-sectional and descriptive study that was carried out in 143 patients with a diagnosis of BPH receiving treatment with tamsulosin and finasteride, selected through non-probabilistic sampling for consecutive cases. The IIEF-5 questionnaire was used for the degree of erectile dysfunction and the Chávez-Velasco scale for the degree of functionality of the conjugal subsystem. The analysis of the results was carried out using descriptive statistics and for the association of the dependent and independent variables Chi square, with a 95% CI and a statistical significance of ≤ 0.05.
Results: The age range was from 45 to 65 years, with 73% married, and the rest in civil union. 135 had some degree of erectile dysfunction and 73 dysfunction of the spousal subsystem.
Conclusions: There is a positive association between erectile dysfunction and the functionality of the conjugal subsystem (p = 0.027).
Downloads
References
Harris E. Foster, MD; Michael J. Barry, MD; Philipp Dahm, MD; Manhar C. Gandhi, MD; Steven A. Kaplan, MD; Tobias S. Kohler, MD; et al. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline. The Journal of Urology. 2018. Vol. 200 (3), 612 – 619. Available from: https://www.auajournals.org/doi/10.1016/j.juro.2018.05.048
W. Pawlina. ROSS, Histología Texto y Atlas. Correlación con Biología Molecular. 7ª ed. Minnesota, Estados Unidos de América, Wolters Kluwer, 2015, pp. 890 – 895.
Keith L. Moore, M. Sc. Ph.D. Arthur F. Dalley, Ph. D, Anne M. R. Agur, B. Sc. MOORE. Anatomía con orientación clínica. 8ª ed. Toronto, Canadá, Wolters Kluwer, 2017, pp. 1108 – 1111.
Bilal Chughtai, James C. Forde, Dominique Dana Marie Thomas, Leanna Laor, Tania Hossack, Henry H. Woo, et al. Benign prostatic hyperplasia. Nature Reviews – Disease Primers. 2016. Vol. 2 (1), Article number: 16032. Available from: https://www.nature.com/articles/nrdp201631
Glenn R. Cunningham, MD, Dov Kadmon, MD. Epidemiology and pathogenesis of benign prostatic hyperplasia. UpToDate. 2019. Available from: https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-benign-prostatic-hyperplasia?search=epidemiology%20and%20pathogenesis%20of%20benign%20prostatic%20hyperplasia&source=search_result&selectedTitle=1~107&usage_type=default&display_rank=1
Sheila Grossman, MD, Carol Mattson Porth, MD. Porth Physiopathology. 9th ed. United States of America, Wolters Kluwer, 2014, pp. 1356 – 1364.
Vinay Kumar, MBBS, MD, Abul K. Abbas, MBBS, Jon C. Aster, MD. Robbins and Cotran Pathologic Basis of Disease, United States of America, EL-SEVIER, 2015, pp. 981 – 990.
David Mobley, Allison Feibus and Neil Baum. Benign prostatic hyperplasia and urinary symptoms: Evaluation and treatment. Postgraduate Medicine. 2015, 127:3, 301-307. Available from: https://www.tandfonline.com/doi/abs/10.1080/00325481.2015.1018799?journalCode=ipgm20
Elsa Reyes Naranjo. Hiperplasia Prostática Benigna. Revista Médica de Costa Rica y Centroamérica. 2013, Vol. 70 (606): 269 – 272. Disponible en: https://www.medigraphic.com/pdfs/revmedcoscen/rmc-2013/rmc132m.pdf
Courtney M. Townsend MD, R. Daniel Beauchamp, MD, B. Mark Evers, MD and Kenneth L. Mattox, MD. Sabiston, Text-book of Surgery: The biological basis of modern surgical practice, 20th ed. Philadelphia, USA. ELSEVIER, 2017. Pp. 2069 – 2071.
Maxine A. Papadakis, Stephen J. McPhee. CURRENT Medical Diagnosis & Treatment, United States of America, McGraw Hill Education, 2019, pp.978 – 989.
Verónica Vergara Méndez, Lidia Bautista – Samperio. Severidad de sintomatología prostática: encuesta de pacientes entre 40 – 60 años. Rev. Fac. Med. UNAM. 2007. Vol. 50. (4), 162 – 164 pp. Disponible en: https://www.medigraphic.com/pdfs/facmed/un-2007/un074d.pdf
Edna G. Delgado – Quiñones, Carlina Pulido-Guerrero, Cristina Navarro – Sandoval, Wendy G. Rivera – Valdivia y Minerva N. Sahagún – Cuevas. Prevalencia de síntomas prostáticos en pacientes mayores de 60 años en una unidad de medicina familiar. Revista Médica MD. 2015, Vol. 6 (4): 263 – 267 pp. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=60320
Sistema Único Automatizado para la Vigilancia Epidemiológica, Dirección General de Salud, Secretaría de Salud, Estados Unidos Mexicanos. Incidencia de Hiperplasia de la próstata (N40) por grupos de edad en población masculina. Anuario 2015. Disponible en: http://www.epidemiologia.salud.gob.mx/anuario/20151/incidencia/enfermedad_grupo_edad_entidad_federa tiva/151.pdf
Eric H. Kim, Jeffrey A. Larson and Gerald L. Andriole. Management of Benign Prostatic Hyperplasia. Annual Reviews Further. 2016. Vol. 67: 137-151. Available from: https://www.annualreviews.org/doi/abs/10.1146/annurev-med-063014-123902
Secretaría de Salud. Diagnóstico y Tratamiento de la Hiperplasia Prostática Benigna, CENETEC, México, 2009. Disponible en: http://www.cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/176_GPC_HIPERPLASIA_PROSTATICA/Gpc_hipertrofia_prostatica.pdf
Hugo López – Ramos, Mauricio Medina – Rico, Danielle Bastidas, Brunno Lara. Tratamiento farmacológico de la hiperplasia prostática benigna. Revisión de la bibliografía. Revista Mexicana de Urología. 2018, Vol. 78 (4): 321 – 334. Disponible en: https://www.medigraphic.com/pdfs/uro/ur-2018/ur184k.pdf
Yohani Pérez Guerra, Vivian Molina Cuevas, Ambar Oyarzábal Yera, Rosa Mas Ferreiro. Tratamiento farmacológico en la hiperplasia prostática benigna. Revista Cubana de Farmacia. 2011, Vol. 45 (1): 109 – 126. Disponible en: http://scielo.sld.cu/pdf/far/v45n1/far12111.pdf
A. García – Vega. Efectos secundarios de los inhibidores de 5 – α reductasa en el tratamiento de hiperplasia prostática benigna. Revista Mexicana de Urología, 2016. Vol. 76 (6): 265 – 266. Disponible en: http://www.redalyc.org/pdf/1491/149143142011.pdf
Yu Seob Shin, Keshab Kumar Karna, Bo Ram Choi, Jong Kwan Park. Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia. The World Journal of Men´s Health. 2019. Vol. 37 (2): 157 – 165. Available from: https://wjmh.org/DOIx.php?id=10.5534/wjmh.180029
Raymond C. Rosen, Francois Giuliano, Culley C. Carson. Sexual Dysfunction and Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH). European Urology. 2005. Vol. 47: 824 – 837. Available from: https://www.europeanurology.com/article/S0302-2838(04)00639-6/fulltext
Arthur L. Burnett, Ajay Nehra, Rodney H. Breau, Daniel J. Culkin, Martha M. Faraday, Lawrence S. Hakim, et al. Erectile Dysfunction: AUA Guideline. The Journal of Urology. 2018, Vol. 3 (1), 633 – 641. Available from: https://www.auajournals.org/doi/10.1016/j.juro.2018.05.004
Dr. Norman Zambrano, Dr. Cristián Palma. Tratamiento de la Hiperplasia Prostática Benigna y de la Disfunción Eréctil por el Médico General. Rev. Med. Clin. Condes. 2018. Vol. 29 (2): 180 – 192. Disponible en: https://www.elsevier.es/es-revista-revista-medica-clinica-las-condes-202-articulo-tratamiento-hiperplasia-prostatica-benigna-disfuncion-S0716864018300300
Luhao Liu, MD, Shankun Zhao, MD, Futian Li, MD, Ermao Li, MD, Ran Kang, MD, Lianmin Luo, MD, et al. Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta – Analysis and Systematic Review of Randomized Controlled Trials. The Journal of Sexual Medicine. 2016. 1 – 14. Available from: https://www.jsm.jsexmed.org/article/S1743-6095(16)30314-9/fulltext
Jason Gandhi, Steven J. Weiss, Noel L. Smith, Steven A. Kaplan, Gautam Dagur, Anna Zumbo, et al. The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. Translational Andrology and Urology. 2017; Vol 6 (2): 295 – 304. Available from: http://tau.amegroups.com/article/view/14174/14811
Alexandre R. Zlotta, MD, Pierre Teillac, MD, Jean P. Raynaud, MD, Claude C. Shulman, MD. Evaluation of Male Sexual Function in Patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a Phytotherapeutic Agent (Permixon®), Tamsulosin or Finasteride. European Urology, 2005, Vol. 48: 269 – 276. Available from: https://www.europeanurology.com/article/S0302-2838(05)00198-3/fulltext
Néstor Carreño – Orellana, Catherina Moll – Manzur, Juan E. Carrasco – Zuber, Sergio Álvarez – Véliz, Daniela Berroeta-Mauriziano, Ninoska Porras – Kusmanic. Efectos adversos de finasteride: mitos y realidades. Una revisión actualizada. Rev. Med. Chile. 2016, Vol. 144: 1584 – 1590. Disponible en: https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0034-98872016001200010
Asociación Española de Andrología (ASESA), Asociación Española d eUrología (AEU), Sociedad Española de Medicina Familiar y Comunitaria (SEMFyC). Documento de consenso sobre disfunción eréctil. SEMERGEN, 2003; 29(5): 255- 63.
Fikret Erdemir, Md. Andrew Harbin, BA, and Wayne Jg Hellstrom, MD. 5-Alpha Reductase Inhibitors and Erectile Dysfunction: The Connection. The Journal of Sexual Medicine. 2008. Vol. 5 (12): 2917 – 2924. Available from: https://www.academia.edu/22008732/5Alpha_Reductase_Inhibitors_and_Erectile_Dysfunction_The_Connection
R. Prieto Castro, P. Campos Hernández, R. Robles Casilda, J. Ruíz García y M. J. Requena Tapia. Epidemiología de la Disfunción Eréctil. Factores de Riesgo. Arch. Esp. Urol. 2010; 63 (8): 637 – 639. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0004-06142010000800010
Mariona Nadal Llover y Cols. Jiménez M. Disfunción sexual causada por medicamentos. FMC. 2017; 24 (5): 265-278. Disponible en: http://residenciamflapaz.com/Articulos%20Residencia%2017/89%20Disfunci%C3%B3n%20sexual%20causada%20por%20medicamentos.pdf
José Luis Huerta González. Medicina familiar: La familia en el proceso salud – enfermedad. 1ª ed. San Luis Potosí, México. Editorial Alfil. 2005. pp: 95 – 104.
Mendoza-Solís LA, Soler – Huerta E, Sainz – Vázquez L, Gil – Alfaro I, Mendoza – Sánchez HF, Pérez – Hernández C. Análisis de la Dinámica y Funcionalidad Familiar en Atención Primaria. Archivos en Medicina Familiar. 2006. Vol. 8 (1) 27 – 32. Disponible en: https://www.medigraphic.com/pdfs/medfam/amf-2006/amf061d.pdf
Moreno Morales MC, Arrieta Pérez R, Luna Domínguez C. Impacto de la disfunción eréctil sobre la funcionalidad del subsistema conyugal del paciente diabético. Archivos en Medicina Familiar. 2008. Vol. 10 82): 42 – 46. Disponible en: https://www.medigraphic.com/pdfs/medfam/amf-2008/amf082d.pdf
Ley General de Salud, en materia de investigación para la salud, [consultado el 10 de septiembre de 2018, http://www.salud.gob.mx/unidades/cdi/legis/lgs/index-indice.htm
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 REMUS - Revista Estudiantil de Medicina de la Universidad de Sonora
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
